Genocea is evaluating GEN-003 for the treatment of herpes simplex virus type 2 (HSV-2), which is the most common cause of genital herpes. The double-blind, placebo-controlled, dose-escalation phase I/IIa study evaluated the safety and immunogenicity of …
|
Comments
Comments are disabled for this post.